Related Experiment Video
Updated: Jun 22, 2025

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
Published on: April 13, 2021
Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies
Guoqian Hu1, Yifan Wu1, Feng Chen2
1Department of Urology, Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.
Abstract:
The immune system can lead to a variety of renal diseases through direct or indirect mechanisms. In immune-mediated nephropathy, though standardized treatment, there are still a small number of patients with further decline in renal function, which may even progress to renal failure; sodium-glucose cotransporter protein 2 (SLC5A2,SGLT2) inhibitors not only can significantly reduce blood glucose, but also have an additional protective effect on the kidneys and the heart; this review concludes the potential mechanism of the renal protective effect of SGLT2i and the new advances in the recent years in common immune-mediated nephropathies, which can provide new theoretical references to optimize the therapeutic strategy of common immune-mediated nephropathies.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Phase II Reactions: Glucuronidation
Secondary Active Transport
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Drugs for Treatment of Ulcerative Colitis in IBD

